Revenue in the pharmaceuticals market by segment France| ��ƽ��

Revenue in the pharmaceuticals market in France from 2016 to 2030, by segment (in million U.S. dollars)

Characteristic	Oncology drugs	Anti-diabetes drugs	Anti-rheumatic drugs	Vaccines	Dermatological drugs	Sensory organs drugs	Immunosuppressants	Antiviral drugs	Bronchodilator drugs	Anti-hypertensive drugs
-	-	-	-	-	-	-	-	-	-	-
-	-	-	-	-	-	-	-	-	-	-
-	-	-	-	-	-	-	-	-	-	-
-	-	-	-	-	-	-	-	-	-	-
-	-	-	-	-	-	-	-	-	-	-
-	-	-	-	-	-	-	-	-	-	-
-	-	-	-	-	-	-	-	-	-	-
-	-	-	-	-	-	-	-	-	-	-
-	-	-	-	-	-	-	-	-	-	-
-	-	-	-	-	-	-	-	-	-	-
-	-	-	-	-	-	-	-	-	-	-
-	-	-	-	-	-	-	-	-	-	-
-	-	-	-	-	-	-	-	-	-	-
-	-	-	-	-	-	-	-	-	-	-
-	-	-	-	-	-	-	-	-	-	-

Download

Source

Show detailed source information?

Already a member?

Sources

More information

Citation formats

In the pharmaceuticals market in France in 2024, the oncology drugs segment generated the highest revenue, reaching approximately ** U.S. dollars. The vaccines segment ranked second with around ** U.S. dollars, while anti-diabetes drugs followed with about ** U.S. dollars.

Other statistics on the topic

Novartis' major drugs based on revenue 2025

Novartis AG's three major drugs 2021-2025, by sales share

Sales forecast of select blockbuster drugs by Novartis worldwide 2028

Sales forecast of select Novartis R&D projects worldwide 2028

Use ��ƽ�� now: unlimited access to all content

Other statistics that may interest you

The most important statistics

Other statistics that may interest you Statistics on

About the industry

About the region

Selected statistics

Other regions

Related statistics

Further Content: You might find this interesting as well

Topics

Novartis

Global pharmaceutical industry

Pharmaceutical industry in the U.S.

Pfizer